Summary
18.30 0.04(0.22%)10/04/2024
Organon & Co (OGN)
Organon & Co (OGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.22 | 7.16 | 19.18 | 7.60 | -22.54 | -43.06 | 0.00 | 28.26 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 18.30 | |
| Open | 18.40 | |
| High | 18.53 | |
| Low | 18.25 | |
| Volume | 1,730,703 | |
| Change | 0.04 | |
| Change % | 0.22 | |
| Avg Volume (20 Days) | 3,595,165 | |
| Volume/Avg Volume (20 Days) Ratio | 0.48 | |
| 52 Week Range | 10.84 - 30.17 | |
| Price vs 52 Week High | -39.34% | |
| Price vs 52 Week Low | 68.82% | |
| Range | 1.08 | |
| Gap Up/Down | 0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,936 | |
| EBIDTA | 2,174,000,128 | |
| PE Ratio | 4.8285 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 40.50 | |
| Book Value | 18.6260 | |
| Earnings Per Share | 5.9750 | |
| EPS Estimate Current Quarter | 1.4300 | |
| EPS Estimate Next Quarter | 1.3800 | |
| EPS Estimate Current Year | 6.3700 | |
| EPS Estimate Next Year | 5.8200 | |
| Diluted EPS (TTM) | 5.9750 | |
| Revenues | ||
| Profit Marging | 0.1926 | |
| Operating Marging (TTM) | 0.2527 | |
| Return on asset (TTM) | 0.1727 | |
| Return on equity (TTM) | -99,999.9900 | |
| Revenue TTM | 7,878,000,128 | |
| Revenue per share TTM | 31.0710 | |
| Quarterly Revenue Growth (YOY) | -0.0080 | |
| Quarterly Earnings Growth (YOY) | -0.4110 | |
| Gross Profit (TTM) | 4,752,000,000 | |
| Dividends | ||
| Dividend Share | 0.2800 | |
| Dividend Yield | 0.0097 | |
| Valuations | ||
| Trailing PE | 4.8285 | |
| Forward PE | 5.0302 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.8433 | |
| Revenue Enterprise Value | 1.9773 | |
| EBITDA Enterprise Value | 7.1193 | |
| Shares | ||
| Shares Outstanding | 253,550,000 | |
| Shares Float | 253,415,647 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.02 | |
| Institutions (%) | 69.00 | |
10/02 19:06 EST - zacks.com
Organon (OGN) Stock Dips While Market Gains: Key Facts
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.
Organon (OGN) Stock Dips While Market Gains: Key Facts
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.
10/02 13:35 EST - youtube.com
Final Trades: Organon, Howmet and the PSQ
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Organon, Howmet and the PSQ
The Investment Committee give you their top stocks to watch for the second half.
09/26 19:05 EST - zacks.com
Why Organon (OGN) Outpaced the Stock Market Today
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
Why Organon (OGN) Outpaced the Stock Market Today
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
09/25 10:00 EST - zacks.com
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
09/18 15:20 EST - benzinga.com
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
09/18 10:59 EST - barrons.com
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
09/18 07:39 EST - reuters.com
Organon to buy therapy developer Dermavant for up to $1.2 billion
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
Organon to buy therapy developer Dermavant for up to $1.2 billion
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
09/18 07:30 EST - businesswire.com
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
09/13 18:56 EST - zacks.com
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
09/12 10:00 EST - zacks.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
09/06 13:46 EST - benzinga.com
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
08/28 10:01 EST - zacks.com
Is Trending Stock Organon & Co. (OGN) a Buy Now?
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Trending Stock Organon & Co. (OGN) a Buy Now?
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
08/14 10:02 EST - zacks.com
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
08/06 12:01 EST - zacks.com
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
08/06 09:56 EST - zacks.com
Organon (OGN) Surpasses Q2 Earnings Estimates
Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago.
Organon (OGN) Surpasses Q2 Earnings Estimates
Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago.
08/03 07:45 EST - invezz.com
Top 4 stocks that could thrive if Kamala Harris wins the 2024 US election
As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump's assertion that Harris would be an easier opponent than Joe Biden, recent developments suggest Harris's presidency is a viable scenario.
Top 4 stocks that could thrive if Kamala Harris wins the 2024 US election
As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump's assertion that Harris would be an easier opponent than Joe Biden, recent developments suggest Harris's presidency is a viable scenario.
08/02 13:11 EST - zacks.com
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
08/01 10:20 EST - zacks.com
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Organon (OGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Organon (OGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
07/31 18:51 EST - zacks.com
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Organon (OGN) closed at $21.86, marking a -1.84% move from the previous day.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Organon (OGN) closed at $21.86, marking a -1.84% move from the previous day.
07/30 11:07 EST - zacks.com
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.